CIK 0001689375
- Accelerated filer
- Smaller reporting company
- Emerging growth company
Entrada Therapeutics, Inc.
Sign in to watch- Ticker
- TRDA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 813983399
- Phone
- +1 857-305-1825
- Business address
- ONE DESIGN CENTER PLACE, SUITE 17-500, BOSTON, MA, 02210
- Former names
- CycloPorters, Inc.
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Open-market buy Director bought 5,000 shares at $5.86 ($29,316)
- 4 Planned sale President, Research & Develop. sold 25,907 shares at $15.39 ($398,810)
- 4 Planned sale President & COO sold 15,000 shares at $15.33 ($229,953)
- 4 Planned sale Chief Financial Officer sold 2,500 shares at $12.95 ($32,375)
- 4 Planned sale President & COO sold 15,010 shares at an average $13.04 ($195,771)
- 4 Planned sale Chief Financial Officer sold 16,477 shares at an average $13.01 ($214,379)
- 4 Planned sale Chief Financial Officer sold 7,988 shares at $12.25 ($97,892)
- 4 Shares withheld for taxes CEO gave up 29,050 shares (to pay taxes)
- 4 Shares withheld for taxes Chief Financial Officer gave up 8,651 shares (to pay taxes)
- 4 Shares withheld for taxes President & COO gave up 21,261 shares (to pay taxes)
- 4 Shares withheld for taxes President, Research & Develop. gave up 11,475 shares (to pay taxes)
- 4 Planned sale Chief Financial Officer sold 8,910 shares at $9.98 ($88,932)
- 4 Open-market buy 10% owner bought 28,867 shares at an average $9.07 ($261,846)
- 4 Open-market sale Director sold 200,000 shares at $8.80 ($1,760,000)
- 4 Open-market sale 10% owner sold 200,000 shares at $8.80 ($1,760,000)
- 4 Open-market buy 10% owner bought 178,044 shares at an average $7.60 ($1,352,587)
- 4 Shares withheld for taxes CEO gave up 8,723 shares (to pay taxes)
- 4 Shares withheld for taxes President & COO gave up 1,746 shares (to pay taxes)
Page 2 of 13 · 242 filings